Vaccine efficacy against Sars-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines
A systematic review
Bibliographic Data
| ID | 22076010 |
|---|---|
| Authors | Lia Reynolds, Cate Dewey (0000-0002-2273-9063), Ghaid Asfour, Matthew Little (0000-0001-6644-2336) |
| Year | 2023 |
| Volume | 11 |
| Publication date | 2023-10-24 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2296-2565 • E-ISSN: 2296-2565 |
| Publisher | Frontiers Media SA (PUBLISHER • CH) |
| DOI | 10.3389/fpubh.2023.1229716 |
| Language | EN |
| Citations received | 2 |
| References cited | 100 |
The purpose of this systematic review was to report on the vaccine efficacy (VE) of three SARS-CoV-2 vaccines approved by Health Canada: Pfizer BioNTech, Moderna, and AstraZeneca. Four databases were searched for primary publications on population-level VE. Ninety-two publications matched the inclusion criteria, and the extracted data were separated by vaccine type: mRNA vaccines (Pfizer and Moderna) and the AstraZeneca vaccine. The median VE for PCR-positive patients and various levels of clinical disease was determined for the first and second doses of both vaccine types against multiple SARS-CoV-2 variants. The median VE for PCR-positive infections against unidentified variants from an mRNA vaccine was 64.5 and 89%, respectively, after one or two doses. The median VE for PCR-positive infections against unidentified variants from the AstraZeneca vaccine was 53.4 and 69.6%, respectively, after one or two doses. The median VE for two doses of mRNA for asymptomatic, symptomatic, and severe infection against unidentified variants was 85.5, 93.2, and 92.2%, respectively. The median VE for two doses of AstraZeneca for asymptomatic, symptomatic, and severe infection against unidentified variants was 69.7, 71, and 90.2%, respectively. Vaccine efficacy numerically increased from the first to the second dose, increased from the first 2 weeks to the second 2 weeks post-vaccination for both doses, but decreased after 4 months from the second dose. Vaccine efficacy did not differ by person's age
Impact and effectiveness of mRNA BNT162b2 vaccine against Sars-CoV-2 infections and Covid-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel
Efficacy and Safety of the mRNA-1273 Sars-CoV-2 Vaccine
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Evaluation of BNT162b2 Vaccine Effectiveness in Galicia, Northwest Spain
Evaluation of the Effectiveness and Safety of the BNT162b2 Covid-19 Vaccine in the Vaccination Campaign among the Health Workers of Fondazione Policlinico Universitario Agostino Gemelli IRCCS
| Citations per year | 1 |
|---|---|
| Citation span | 2024 - 2024 (1) |
| Highly cited | No |